2. Amyotrophic lateral sclerosis Clinical trials / Disease details

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

  
3 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05597436
(ClinicalTrials.gov)		November 19, 202224/10/2022Intermediate-Sized Expanded Access StudyAn Expanded Access Protocol of Intravenous Trehalose Injection 90.5 mg/mL Treatment of Patients With Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisDrug: TrehaloseSeelos Therapeutics, Inc.Massachusetts General Hospital;National Institute of Neurological Disorders and Stroke (NINDS);Office of the Director, National Institutes of Health (OD)Temporarily not available18 YearsN/AAllUnited States
2NCT05136885
(ClinicalTrials.gov)		February 21, 202214/11/2021HEALEY ALS Platform Trial - Regimen E SLS-005 - TrehaloseHEALEY ALS Platform Trial - Regimen E SLS-005 - TrehaloseAmyotrophic Lateral SclerosisDrug: SLS-005;Drug: Matching PlaceboMerit E. Cudkowicz, MDSeelos Therapeutics, Inc.Enrolling by invitation18 YearsN/AAll160Phase 2/Phase 3United States
3NCT04297683
(ClinicalTrials.gov)		July 14, 20203/3/2020HEALEY ALS Platform Trial - Master ProtocolHEALEY ALS Platform TrialAmyotrophic Lateral SclerosisDrug: Zilucoplan;Drug: Verdiperstat;Drug: CNM-Au8;Drug: Pridopidine;Drug: SLS-005 TrehaloseMerit E. Cudkowicz, MDMassachusetts General HospitalRecruiting18 YearsN/AAll800Phase 2/Phase 3United States